ER positive breast cancer often responds well to hormone therapy and may indicate a better prognosis than negative cases.
Suitable for use as the primary antibody with the labeled streptavidin-biotin (LAB-SA) (1,2) detection method or equivalent method.
Suitable for use in Immunohistochemistry. Other applications not tested.
Immunohistochemistry: In general, immunohistochemical (IHC) staining techniques allow for the visualization of antigens in frozen and paraf n-embedded tissues via the sequential application of a speci c antibody to the antigen (primary antibody), a biotinylated antibody to the primary antibody (secondary antibody), an enzyme conjugate (tertiary component) and a chromogenic substrate with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope.
Optimal dilutions to be determined by the researcher.
Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and add glycerol (40-50%). Freeze at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
| As reported|
|Recombinant estrogen receptor (ER) protein|
|Purified by Protein A affinity chromatography.|
|Supplied as a liquid in PBS, 1% BSA, and 0.1% sodium azide.|
|Recognizes the N-terminal (A/B region) of the estrogen receptor. It also reacts with the cytosolic extracts of luteal endometrium and the human breast cancer cell line MCF-7. This antibody labels epithelial cells of some breast cancers which express ER.|
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|
1. Elias JM. (1984) Am J Clin Pathol 92:62-67. 2. Shi, ZR et al. (1988) J of Histochemistry and Cytochemistry 36(3):317-322. 3. Kumar, V et al. (1987) Cell 51:941-951. 4. Al Saati, T et al. (1993) Int J Cancer 55:651-654. 5. College of American Pathologists (CAP) Certification Program for Immunohistochemistry. CAP. Northfield, IL. Http://www.cap.org 6. O’Leary, T.J. et al. Quality assurance for immunocytochemistry; Proposed guideline. MM4-P. National Committee for Clinical Laboratory Standards (NCCLS). Wayne, PA. 1-46, 1997. 7. Clinical Laboratory Improvement Amendments of 1988: Final Rule, 57 FR 7163, February 28, 1992. 8. Elias, J.M. et al. (1989) Special Report: Quality Control in immunohistochemistry. Am J Clin Path 92:836. 9. Kiernan, J.A. Histological and Histochemical Methods: Theory and Practice. New York: Pergamon Press, 1981. 10. Sheehan, D.C. and Hrapchak, B.B. Theory and Practice of Histotechnology. St. Louis: C.V. Mosby Co., 1980. 11. Taylor and Cote. Immunomicroscopy: A Diagnostic Tool for the Surgical Pathologist. 2nd Ed. W.B. Saunders Co. Philadelphia, 1994.|